Dennis Fenton Nominated for Election to
Genzyme’s Board of Directors
25-Year Amgen Veteran Helped Build World-Class Biologics Manufacturing Operations
June 07, 2010 07:58 AM Eastern Daylight Time
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Genzyme Corporation (NASDAQ: GENZ) today
announced that the Nominating and Corporate Governance Committee of its board of directors has nominated
Dennis M. Fenton, Ph.D., for election to the board. Mr. Fenton was executive vice president of operations at
Amgen when he retired from the company in 2008. The nomination fulfills the commitment made by Genzyme as part
of the agreement announced in April with Relational Investors, LLC to nominate an independent director
recommended by Relational with substantial expertise in biopharmaceutical manufacturing and operations.
Mr. Fenton, 58, is a highly regarded leader in manufacturing and established much of the biologics operating
protocol that is standard practice in the industry today. He joined Amgen during its first year of operation and led
virtually every functional area of the company during his 25-year tenure. His broad experience includes executive
leadership roles in operations, manufacturing, engineering, process development, quality, sales and marketing,
research, and information management.
At Amgen, Mr. Fenton played a key role in the company’s growth from a small start-up to a leading global
biotechnology company with one of the most reliable, efficient and skilled manufacturing operations in the world. He
coordinated the design, construction and expansion of manufacturing facilities for Epogen® (epoetin alfa) and
Neupogen® (filgrastim), two of the premier products in the biotechnology industry.
“We are excited by the prospect of having Dennis Fenton join our board of directors and commend Relational for its
prompt and thoughtful recommendation,” said Henri A. Termeer, Genzyme’s chairman and chief executive officer.
“Dennis will bring to our board the precise type of expertise that we n